-
Healthcare
-

The Quiet Consolidation Of Healthcare's Digital Plumbing, And What It Means For The NHS's Own Vendor Bet

By
Distilled Post Editorial Team

In a New York press release that will have registered with almost nobody in Whitehall, an IBM spin-off called Kyndryl announced this month that it intends to buy a company called Healthcare IT Leaders. The target is modest. It advises American hospitals on clinical software and workforce platforms. The acquirer is not modest at all. Kyndryl runs the mainframes, networks and cloud migrations behind a large share of the world's most complex institutions, including, since 2023, a slice of HMRC's tax infrastructure through the government's G-Cloud framework. The logic behind the purchase, stated plainly by its US president, is that hospitals no longer want separate contracts for infrastructure, applications and artificial intelligence. They want one supplier who owns the lot.

That sentence should sound familiar to anyone who has followed the last three years of NHS digital policy, because it is precisely the argument used to justify the Federated Data Platform and its central role for Palantir. The case for consolidation is not hard to make. Trusts have spent two decades assembling patchworks of electronic patient records, imaging systems, rostering tools and now AI pilots, each procured separately, each requiring its own integration budget and its own security sign-off. A single vendor promises to collapse that complexity into one relationship, one invoice and, in theory, one point of accountability when something breaks. Kyndryl's move confirms that this is not a peculiarly British experiment. It is where the entire health IT services market is heading, and the providers building these stacks are the same firms competing for NHS work.

What consolidation buys in simplicity, it spends in leverage of a different kind: negotiating leverage, held by the vendor rather than the client. When infrastructure, applications and AI sit inside one contract, switching costs stop being a technical inconvenience and become close to structural. This is already visible in the recurring warnings about NHS dependence on Epic-specific clinical systems, where workforce training, data architecture and even litigation over staff mobility now trail behind a single software choice. Add AI-led modernisation into that same contract, procurement decisions that were once separable, who hosts the data, who builds the algorithm, who manages the servers it runs on, collapse into a single supplier relationship that becomes progressively harder to unwind the longer it runs.

For NHS leadership, currently absorbed by NHS England's dissolution into the Department of Health and Social Care and by Integrated Care Board consolidation under Sir Jim Mackey, this ought to sharpen a question that has so far been treated mainly as an information governance matter. It is a market structure matter. A health system negotiating with a handful of global infrastructure firms that are themselves racing to become full-stack providers is negotiating from a different position than one dealing with several specialised suppliers, each replaceable on its own terms. The Cabinet Office's own scepticism about single-supplier public contracts, sharpened by outsourcing failures over the past decade, sits uneasily against a digital strategy that keeps deepening reliance on platforms designed precisely to be difficult to leave.

None of this means Kyndryl itself will ever touch an NHS trust's clinical systems, and the deal's UK relevance should not be overstated. But procurement teams inside DHSC and NHS England's successor functions are watching the same market Kyndryl is betting on, and drawing conclusions about what "AI-led modernisation" contracts will look like when the next wave of NHS tenders goes out. If the market's answer to healthcare's operational strain is fewer, larger, more entangled vendors, the NHS needs a procurement posture that treats consolidation as a risk to be priced, not a convenience to be welcomed. The alternative is discovering, several years and several billion pounds into a platform relationship, that the exit was never really available. Health systems on both sides of the Atlantic are learning the same lesson at different speeds. Britain has less excuse for learning it late.